Results 51 to 60 of about 328,808 (245)

Cell line derived xenograft mouse models are a suitable in vivo model for studying tumor budding in colorectal cancer [PDF]

, 2019
Tumor budding (TB) is an important prognostic parameter in colorectal cancer (CRC) and associated with metastasis. However, the mechanisms of TB have not been fully elucidated and a major limitation is the absence of in vivo models.
Dawson, Heather, De Wever, Olivier, Demetter, Pieter, Galván, José A., Georges, Laurent M. C., Lugli, Alessandro, Zlobec, Inti   +6 more
core   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]

, 2014
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Bown, James L., Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Hu, Huizhong, Khalil, Hilal S., Kyriakidis, Stylianos, Langdon, Simon P., Soininen, Tero   +8 more
core   +6 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Osteocalcin and Runx2 expression in anterior maxillary reconstructions using bone xenografts associated to bone marrow aspirate concentrate

Contemporary Clinical Dentistry, 2022
Background: It is known that a large number of mediators involved in osteogenesis can influence bone development and repair; however, whether these mediators could be used as markers of bone maturity has yet to be determined.
Daniel Fernando Hergemöller, André Antonio Pelegrine, Paulo José Pasquali, Luis Guilherme Scavone de Macedo, Marcelo Lucchesi Teixeira, Peter Karyen Moy, Antonio Carlos Aloise   +6 more
doaj   +1 more source

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]

, 2017
Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W, Duan, Zhijian, Ho, Pui Yan, Jian, Chao, Lam, Kit S, Lara, Primo N, Qiu, Jing-Xin, Tu, Mei-Juan, Wun, Theodore, Yu, Ai-Ming, Yu, Ai-Xi, Zhang, Qianyu   +11 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease

Biomolecules
Multiple myeloma (MM) is a plasma cell malignancy that disrupts bone homeostasis by suppressing osteogenesis and promoting osteoclast activity. While most therapeutic interventions to date have focused on targeting tumor cells and reducing osteolysis, we
Jiaxian Wang, Thomas Baardemans, Ricardo de Matos Simoes, Willy Noort, Ruud W. J. Ruiter, Henk-Jan Prins, Susan E. van Hal-van Veen, Huipin Yuan, Joost D. de Bruijn, Anton C. M. Martens, Constantine S. Mitsiades, Sonja Zweegman, Maria Themeli, Richard W. J. Groen   +13 more
doaj   +1 more source

Current Barriers to Clinical Liver Xenotransplantation

Frontiers in Immunology, 2022
Preclinical trials of pig-to-nonhuman primate liver xenotransplantation have recently achieved longer survival times. However, life-threatening thrombocytopenia and coagulation dysregulation continue to limit preclinical liver xenograft survival times to
Arthur A. Cross-Najafi, Kevin Lopez, Abdulkadir Isidan, Yujin Park, Wenjun Zhang, Ping Li, Sezai Yilmaz, Sami Akbulut, Burcin Ekser   +8 more
doaj   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source